GlassScriptPhysician profile
Joe E Najjar
NPI 1659316289
$15,214.52
in general payments reported to CMS, 2019-2025
42 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,830 · 2021: $2,447 · 2022: $2,266 · 2023: $2,236 · 2024: $1,966 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,642 · Education: $66.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,642.13 |
| Education | $66.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,603.81 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $2,753.13 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Janssen Biotech, INC. | $1,142.77 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $1,072.96 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Novo Nordisk INC | $754.46 | 2019-2025 | Ozempic, Rybelsus |
| Insmed, INC. | $710.43 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $685.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $623.71 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Theratechnologies INC. | $422.30 | 2019-2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $407.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Emd Serono, INC. | $283.90 | 2019-2025 | Serostim |
| Janssen Products, LP | $255.47 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $211.16 | 2020-2021 | |
| Mannkind Corporation | $179.24 | 2022-2025 | Afrezza |
| Amgen INC. | $167.37 | 2019-2025 | Repatha, Otezla, Evenity |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Najjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.